Thank you for being a part of our Open Medicine Foundation family. As we reflect on the achievements of the past year, I would like to honor the memory of Ronald Tompkins, MD, ScD, OMF’s beloved Chief Medical Officer and Director of the Harvard Collaborative, who helped make so many of these accomplishments possible over the years.
With heavy hearts, we announced the news of Ron Tompkins’s sudden and unexpected passing on January 17th, 2022. I join Ron’s family, friends, and all who knew Ron, in being deeply heartbroken by this tragedy.
Ron was not only a wonderful, caring friend and colleague with whom I shared endless hours brainstorming ideas, but he was a leader, a mentor, and a brilliant physician, scientist, and entrepreneur. He had a genuine passion and mission to help as many people as possible. I cannot begin to express how much he will be missed.
I met Ron Tompkins when Ron Davis asked him to join our OMF Scientific Advisory Board in 2014. He joined with his whole heart and we became instant friends.
We vow to continue Ron’s legacy at OMF in all we do and at the newly named Ronald G. Tompkins ME/CFS Research Collaboration. In his honor, we will continue to help as many people as possible and find treatments for millions suffering from these multisystem chronic complex diseases (msCCD), including ME/CFS, and now Long COVID.
Through this difficult time, I sincerely thank you for being part of our mission to improve the lives of millions living with these debilitating diseases; a cause so close to Ron’s heart. I also want to thank the patient-participants. Without you, there would be no research. And thank you to all the dedicated researchers, OMF staff, volunteers, and board members that help us get closer to our vision every day.
With hope for all,
Linda Tannenbaum
Founder & CEO/President
Remembering Ron:
A Champion of ME/CFS Research, and Friend to All
A Year of Powerful Research Progress 🔬
OMF Funded ME/CFS Collaborative Research Center Updates of 2021
Thanks to our supporters, we helped advance groundbreaking research in 2021 at the six OMF funded Collaborative Research Centers across the globe.
We Established a Sixth Research Center!
As part of our mission to fund and facilitate urgent, open, and collaborative research, in 2021 OMF added a sixth center to our international OMF Collaborative Research Network to accelerate computational analysis.
Under the direction of Wenzhong Xiao, PhD, the newly established Computational Research Center for Complex Diseases analyzes and provides critical information and insights into projects being conducted at the other five OMF funded research centers at Stanford, Harvard, Uppsala, Montreal, and Melbourne.
Learn more about the Computational Research Center for Complex Diseases.
Hosted a Virtual Open House for the Community
In May 2021, OMF hosted a virtual event to update our OMF funded Collaborative Research Centers. Our “Virtual Open House” was a success, with thousands tuning in to hear the latest updates from the six Directors.
Watch it now on YouTube.
Funded Groundbreaking New Studies
Over 25 OMF funded research projects are currently underway! In 2021 alone, we funded thirteen new projects, including:
- Neuroinflammation Study into “Brain Fog”
- Viral Risk Factors in ME/CFS
- Identification of switches/traps in ME/CFS nitrogen metabolism
- Sleep Disturbances in ME/CFS
- Computational Analysis for CRC Studies
- pRecision mEdicine for Myalgic Encephalomyelitis Drug dIscovery and clinicAl triaLs (REMEDIAL)
- Continued Development of the Personalized Automated Symptom Summary Computerized Adaptive Test (PASS-CAT)
- Analysis of Proteomics, Metabolomics, and Nitrogen Assays of Cerebrospinal Fluid and Whole Blood samples, in ME/CFS Patients
- Development of a New Microfluidic Diagnostic Device for ME/CFS
- Study of COVID- 19 survivors’ Profiles for detection of M.E.
- Deep proteome and Metabolome profiling to decode M.E.
- Identifying Objective Behavioral Markers of Deficit in Patients with ME/CFS via Ocular Motor Study
- Identifying Disease Development Pathways and Exacerbating Factors
To learn more about some of these major research initiatives taking place across the six OMF funded Research Centers, please visit The End ME/CFS Project Webpage.
Awards, News Features, & Community in Action
Open Medicine Foundation is proud to have received the following accolades:
- 2021 “Top-Rated Nonprofit” recognition by Great Nonprofits
- Platinum level recognition from Guidestar for our commitment to transparency.
- Two scores of “100 Encompass Rating” from Charity Navigator in Finance & Accountability and Leadership & Adaptability.
- OMF was featured on South African News Channel, Carte Blanche! This report highlights OMF’s research efforts to investigate the connection between ME/CFS and Long COVID. Watch the full segment.
- A publication by Dr. Alain Moreau, PhD of the OMF Montreal Collaborative was named one of the top 100 Scientific Reports papers in 2020. It is entitled “Profile of circulating microRNAs in Myalgic Encephalomyelitis and their relation to symptom severity, and disease pathophysiology.”
- OMF Ambassador Jennie Jacques bravely shared her journey living with ME/CFS in The Times
New Tool to Educate your Personal Community
In September of 2021, OMF unveiled our Social Shareables web portal, a new tool to help you educate your personal communities about ME/CFS and related multisystem chronic, complex diseases (msCCD).
The Social Shareables page can be used to download educational graphics and sample text posts about ME/CFS, Fibromyalgia, Long COVID, and Chronic Lyme Disease. You can share these posts directly on social media to raise awareness.
Thank you for being a part of the OMF family! If you are able, please consider contributing to our groundbreaking research efforts in 2022 so that we can finally find answers for millions suffering from ME/CFS and related chronic, complex diseases.
Donate your appreciated stock directly to OMF and you can receive an immediate income-tax deduction for the fair market value of the securities on the date of transfer (even if you originally paid much less for them).